Evidence map›Paper›PMID 22065224›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2012

Affinity-based profiling of dehydrogenase subproteomes.

Xia Ge, Daniel S Sem

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Xia GeChemical Proteomics Facility at Marquette, Department of Chemistry, Marquette University, Milwaukee, WI, USA.
Daniel S Sem
Marquette University · USUniversity of Wisconsin System · US

Funding

600 MHz Nuclear Magnetic Resonance SpectrometerS10RR019012 · NCRR · MARQUETTE UNIVERSITY · PI SEM, DANIEL S · 2005 to 2005
$500k
Implications of Binding Synergy for Fragment Assembly: A Dynamics PerspectiveR15GM085739 · NIGMS · MARQUETTE UNIVERSITY · PI SEM, DANIEL S · 2009 to 2009
$218k
NCRR NIH HHS S10 RR019012NIGMS NIH HHS GM085739NIGMS NIH HHS R15 GM085739
6 · The paper itself

Abstract

The high cost of drug discovery and development requires more efficient approaches to the identification and inhibition of tractable protein targets. One strategy is to pursue families of proteins that already possess affinity for a drug lead scaffold, where that scaffold plays the dual role of serving (a) when tethered to a resin, as a ligand to purify a subproteome of interest, and (b) as a lead molecule that has the potential for optimization for a given member of the subproteome. Here, we describe an example of the purification of a subproteome using a scaffold tailored to the dehydrogenase family of enzymes. Combined with modern LC-MS/MS methods and subsequent searching of proteome databases, such affinity chromatography strategies can be used to purify and identify any proteins with affinity for the scaffold molecule. The method is exemplified using the CRAA (catechol rhodanine acetic acid) privileged scaffold, which is tailored to dehydrogenases. CRAA affinity column chromatography, combined with LC-MS/MS, is described as a method for profiling dehydrogenase subproteomes.

Indexed as

Chromatography, AffinityEstersMycobacterium tuberculosisOxidoreductasesProteomeProteomicsRhodanineSepharoseSuccinimidesTandem Mass SpectrometryEstersN-hydroxysuccinimideOxidoreductasesProteomeRhodanineSepharoseSuccinimides

Identifiers

PMID22065224
PMCPMC4092038
OpenAlexW1433193271

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.